Analysts See $0.02 EPS for Nuvo Pharmaceuticals Inc. (NRI); Retirement Systems Of Alabama Cut By $1.18 Million Its Wells Fargo Co New (WFC) Stake

April 17, 2018 - By Peter Mason

Wells Fargo & Company (NYSE:WFC) Logo

Analysts expect Nuvo Pharmaceuticals Inc. (TSE:NRI) to report $0.02 EPS on May, 9.They anticipate $0.17 EPS change or 89.47% from last quarter’s $0.19 EPS. T_NRI’s profit would be $231,015 giving it 41.13 P/E if the $0.02 EPS is correct. After having $-0.02 EPS previously, Nuvo Pharmaceuticals Inc.’s analysts see -200.00% EPS growth. The stock decreased 0.30% or $0.01 during the last trading session, reaching $3.29. About 9,048 shares traded. Nuvo Pharmaceuticals Inc. (TSE:NRI) has 0.00% since April 17, 2017 and is . It has underperformed by 11.55% the S&P500.

Retirement Systems Of Alabama decreased Wells Fargo Co New (WFC) stake by 0.75% reported in 2017Q4 SEC filing. Retirement Systems Of Alabama sold 19,724 shares as Wells Fargo Co New (WFC)’s stock declined 16.98%. The Retirement Systems Of Alabama holds 2.61 million shares with $158.38 million value, down from 2.63 million last quarter. Wells Fargo Co New now has $246.72 billion valuation. The stock decreased 0.35% or $0.18 during the last trading session, reaching $50.62. About 16.68 million shares traded. Wells Fargo & Company (NYSE:WFC) has declined 7.75% since April 17, 2017 and is downtrending. It has underperformed by 19.30% the S&P500.

Nuvo Pharmaceuticals Inc., a commercial healthcare company, produces and sells pharmaceutical products in the United States, Canada, and Europe. The company has market cap of $38.00 million. It offers Pennsaid, a topical pain product that is used to treat the signs and symptoms of osteoarthritis of the knee; Pennsaid 2%, a follow-on product to Pennsaid for the treatment of the pain of osteoarthritis of the knee; and Heated Lidocaine/Tetracaine Patch, a topical patch that provides local analgesia prior to painful needle procedures, such as dialysis, blood draws, and pediatric needles. It has a 26.53 P/E ratio. The firm was formerly known as Nuvo Research Inc. and changed its name to Nuvo Pharmaceuticals Inc. in March 2016.

Among 39 analysts covering Wells Fargo & Company (NYSE:WFC), 15 have Buy rating, 9 Sell and 15 Hold. Therefore 38% are positive. Wells Fargo & Company had 145 analyst reports since July 29, 2015 according to SRatingsIntel. The rating was upgraded by Citigroup on Thursday, January 7 to “Buy”. The firm has “Neutral” rating by UBS given on Wednesday, January 11. The stock of Wells Fargo & Company (NYSE:WFC) earned “Hold” rating by BMO Capital Markets on Friday, January 12. Guggenheim upgraded the shares of WFC in report on Wednesday, April 26 to “Neutral” rating. Credit Suisse downgraded the stock to “Neutral” rating in Thursday, February 16 report. The rating was maintained by BMO Capital Markets with “Hold” on Friday, April 13. Atlantic Securities upgraded the stock to “Neutral” rating in Wednesday, January 10 report. The firm earned “Hold” rating on Sunday, February 4 by BMO Capital Markets. The stock of Wells Fargo & Company (NYSE:WFC) earned “Buy” rating by Nomura on Thursday, September 28. The firm has “Buy” rating by RBC Capital Markets given on Friday, October 6.

Analysts await Wells Fargo & Company (NYSE:WFC) to report earnings on July, 13. They expect $1.17 earnings per share, up 9.35% or $0.10 from last year’s $1.07 per share. WFC’s profit will be $5.70 billion for 10.82 P/E if the $1.17 EPS becomes a reality. After $1.12 actual earnings per share reported by Wells Fargo & Company for the previous quarter, Wall Street now forecasts 4.46% EPS growth.

Since November 17, 2017, it had 0 buys, and 1 sale for $292,234 activity. Codel Franklin R sold $292,234 worth of Wells Fargo & Company (NYSE:WFC) on Friday, November 17.

Wells Fargo & Company (NYSE:WFC) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Peter Mason

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: